gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Recommended For You
Breast CancerPatient Stories
You Never Think It Will Happen to You
By Regina Groce
Regina Groce, a young wife and mother, thought her life was everything it was supposed to be, until a devastating phone call after surgery to remove a lump in her breast revealed she was carrying the BRCA mutation.
Breast CancerImmunotherapyMetastatic Breast Cancer
Immunotherapy plus Chemotherapy Extends Survival for Patients with Metastatic Triple-Negative Breast Cancer
By Dana Taylor
Triple-negative breast cancer has few treatment options. Promising results from recent clinical trials of immunotherapy combined with chemotherapy in patients with metastatic disease may soon change the way this aggressive cancer is treated. Just after this article was written, the FDA approved this combination for patients with triple-negative breast cancer.
Breast Cancer
Drugs for Breast Cancer
Here are the drugs and financial support services available to patients receiving treatment for Breast Cancer.
Last modified: March 25, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country